CCM
NYSEConcord Medical Services Holdings Limited
Price$4.71+1.19 (+33.81%)
2026-03-042026-06-05
News · 26 weeks12-75%
2025-12-142026-06-07
Mix1290d
- Insider6(50%)
- SEC Filings4(33%)
- Other2(17%)
Latest news
25 items- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025BEIJING, April 29, 2026 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission ("SEC"). An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to
- SECSEC Form 20-F filed by Concord Medical Services Holdings Limited20-F - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- INSIDERSEC Form 3 filed by new insider Yang Jianyu3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Medical Schedules 2025 Annual Meeting of ShareholdersBEIJING, Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time). The meeting will be held at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, China. The shareholder record date is December 19, 2025. A copy of the notice of Meeting is available on the Company's investor relations website at https://ir.ccm.cn. No proposal will be submitted
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Medical Reports Financial Results for the First Half of 2025BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant MelanomaBEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effect
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
CCM FAQ
6 questionsWhat does Concord Medical Services Holdings Limited do?
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in Network and Hospital segments. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. It also offers other treatments and diagnostic services comprising electroencephalography for the diagnosis of epilepsy; thermotherapy for pain relief after radiotherapy and...Where does CCM stock trade?
Concord Medical Services Holdings Limited (CCM) is listed on NYSE.What sector and industry is CCM in?
Concord Medical Services Holdings Limited operates in the Health Care sector, Medical/Nursing Services industry.When did Concord Medical Services Holdings Limited go public?
Concord Medical Services Holdings Limited (CCM) completed its IPO in 2024.What companies are similar to CCM?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), HIMS (Hims & Hers Health Inc.), CHE (Chemed Corp), AMED (Amedisys Inc), LHCG (LHC Group). Compare CCM side-by-side with any of them on Quantisnow.How can I track CCM on Quantisnow?
Quantisnow aggregates Concord Medical Services Holdings Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CCM to receive live email and push alerts on every new disclosure.